Inhibition of the Bcl-xLDeamidation Pathway in Myeloproliferative Disorders
نویسندگان
چکیده
منابع مشابه
Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.
BACKGROUND The myeloproliferative disorders are clonal disorders with frequent somatic gain-of-function alterations affecting tyrosine kinases. In these diseases, there is an increase in DNA damage and a risk of progression to acute leukemia. The molecular mechanisms in myeloproliferative disorders that prevent apoptosis induced by damaged DNA are obscure. METHODS We searched for abnormalitie...
متن کاملOncogenes in myeloproliferative disorders.
Myeloproliferative disorders (MPDs) constitute a group of hematopoietic malignancies that feature enhanced proliferation and survival of one or more myeloid lineage cells. William Dameshek is credited for introducing the term "MPDs" in 1951 when he used it to group chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) under one cl...
متن کاملthe effect of the record infancy in crimilly acts of guilties (in karaj city)
چکیده یکی از مهمترین دغدغه های بزرگ جوامع بشری، از دیر باز تا کنون که ذهن پژوهشگران و متخصصان بهداشت روانی و اجتماعی و دولتها رابه خود مشغول داشته، مسأله ی بزهکاری می باشد. شناخت کامل پدیده ی بزهکاری و بزهکار، علل وعوامل سقوط یک انسان، چگونگی درمان وی و درنهایت پیشگیری ازبزهکاری ودریک کلام سالم سازی یک جامعه، رسالت عظیم، انسانی ومقدسی می باشد که با بررسی شخصیت مجرم یعنی[ انسانی که تحت شرای...
15 صفحه اولMyeloproliferative disorders and its associated mutations
Myeloproliferative Neoplasm (MPN) are a clonal disorder in hematopoietic stem cells (HSC). MPN is categorized to 8 subclasses, including chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocytopenia (ET), primary myelofibrosis (PMF), systematic mastositosis (SM), chronic eosinophilic leukemia (CEL), chronic neutrophilic leukemia (CNL), and unclassified myelofibrosis disorde...
متن کامل32P in the treatment of myeloproliferative disorders
UNLABELLED (32)P has been available for the treatment of myeloproliferative neoplasms (MPNs) for over seventy years. It was first used in 1938 by John H Lawrence in the treatment of polycythaemia and chronic leukaemias. With the introduction of agents such as hydroxycarbamide, interferon and anagrelide the role of (32)P has been diminished. Today, Polycythaemia Rubra Vera (PRV) and Essential Th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: New England Journal of Medicine
سال: 2008
ISSN: 0028-4793,1533-4406
DOI: 10.1056/nejmoa0804953